This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
messenger-rna: Archive
STMicroelectronics (STM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
STMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HFCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DISHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ALGTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Xilinx (XLNX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
XLNXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile momentum-investor momentum-stocks oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked vaccines
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MPWRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile momentum-investor momentum-stocks oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked vaccines
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AMPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile momentum-investor momentum-stocks oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked vaccines
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AEMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile momentum-investor momentum-stocks oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media top-ranked vaccines
Is T. Rowe Price Japan Fund (PRJPX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for PRJPX
PRJPXNegative Net Change
equity immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is Fidelity Blue Chip Growth (FBGRX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for FBGRX
FBGRXNegative Net Change
equity immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is T. Rowe Price Health Sciences (PRHSX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for PRHSX
PRHSXPositive Net Change
equity immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is Kinetics Global Fund No Load (WWWEX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for WWWEX
WWWEXPositive Net Change
equity immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is Vanguard Wellesley Income Investor (VWINX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for VWINX
VWINXPositive Net Change
equity immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Should Invesco S&P 500 Enhanced Value ETF (SPVU) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPVU
SPVUPositive Net Change TPositive Net Change WMTPositive Net Change VTVPositive Net Change IWDPositive Net Change
dividend etf expenses gambling holdings immuno-therapy index market-capitalization medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Should You Invest in the iShares U.S. BrokerDealers & Securities Exchanges ETF (IAI)?
by Zacks Equity Research
Sector ETF report for IAI
IAIPositive Net Change GSNegative Net Change MSPositive Net Change ICEPositive Net Change KCENegative Net Change
apparel dividend etf expenses hmo holdings hospitals immuno-therapy index medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media us-equities vaccines
Is iShares MSCI Intl Multifactor ETF (INTF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for INTF
INTFPositive Net Change INVEPositive Net Change VEAPositive Net Change VXUSPositive Net Change
dividend etf expenses holdings immuno-therapy index medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Why SAIC (SAIC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SAICPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy growth-investing growth-investors growth-stocks high-growth home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Why Centene (CNC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CNCPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy growth-investing growth-investors growth-stocks high-growth home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Down 10.2% in 4 Weeks, Here's Why Fidelity National (FIS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Fidelity National (FIS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FISPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing rsi saas self-driving-cars smart-health social-media stock-price-movement vaccines
Down 12.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Global Payments (GPN)
by Zacks Equity Research
Global Payments (GPN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GPNNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing rsi saas self-driving-cars smart-health social-media stock-price-movement vaccines
New to Investing? This 1 Basic Materials Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
CEPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-estimates fin-tech furniture-retailers gene-editing gene-therapy growth-investing home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines zacks-consensus-estimate zacks-rank
Why Capital One (COF) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
COFPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NVSPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna momentum-investor momentum-stocks oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Toyota Motor Corporation (TM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Toyota Motor Corporation (TM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TMPositive Net Change
automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change ride-hailing saas self-driving-cars smart-health social-media style-scores vaccines valuation
Volt Information (VOLT) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Volt Information (VOLT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
VOLTNegative Net Change
automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change ride-hailing saas self-driving-cars smart-health social-media style-scores vaccines valuation